SAN FRANCISCO and SUZHOU, China, May 18, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a global leader in biopharmaceutical innovation delivering transformative therapies for oncology, cardiovascular and metabolic, autoimmune, and ophthalmological diseases, today unveiled its 2024 Environmental, Social, and Governance (ESG) Report. The report outlines a robust five-pillar framework—”Excellent Governance,” “Advancing Public Health,” “Uncompromising Quality,” “Empowering Talent,” and “Sustainable Ecology”—as the foundation for its commitment to aligning corporate growth with societal progress.
Dr. Michael Yu, Founder, Chairman, and CEO of Innovent, remarked: “As one of the few biotech companies globally to achieve an MSCI ESG rating of AAA—and the only one in China—we’ve embedded sustainability into every stratum of our operations. By merging cutting-edge innovation with responsible governance, we’re not just navigating the future of healthcare; we’re setting benchmarks for an industry that prioritizes people, planet, and long-term value creation.”
In 2024, Innovent formalized its alignment with United Nations Sustainable Development Goals (SDGs), strengthened boardroom diversity, and launched initiatives accelerating equitable access to life-saving treatments. “Our mission transcends commercial success,” Yu added. “We aim to redefine what biopharma leadership looks like in a world demanding both scientific breakthroughs and ethical stewardship.”
Building an ESG-Centric Operating Model
At the core of Innovent’s governance strategy lies a dynamic framework designed to adapt to global regulatory shifts while upholding transparency. Key milestones included establishing gender-balanced board committees, achieving 100% ethics training compliance, and ensuring all suppliers adhere to ironclad business conduct standards through binding agreements.
Notable achievements:
- Expanded board diversity with the appointment of a female Executive Director
- 100% ethics training completion rate across directors and employees
- Launch of a public ESG portal, enhancing stakeholder transparency
- Recognition as one of only three biotechs worldwide—and the sole Chinese recipient—of MSCI’s elite AAA ESG rating
Innovation as a Catalyst for Healthcare Equity
Innovent’s R&D pipeline continues reshaping treatment landscapes, particularly in underserved areas. Its thyroid eye disease therapy SYCUME® marked China’s first IGF-1R antibody approval in 70 years, while orphan drug designations for 13 candidates highlight its focus on rare diseases. Beyond patents, the company’s patient assistance programs have distributed medicines valued at RMB 3.6 billion, benefiting over 200,000 individuals.
- 6 drugs listed in China’s National Reimbursement Drug List (NRDL), including SINTBILO®—now the first domestic PCSK9 inhibitor covered
- 15 commercial products reaching 5 million patients globally
- 3 New Drug Applications (NDAs) under regulatory review and 4 in Phase III trials
- Expansion of Huimin Insurance partnerships to cover 8 critical therapies
- Rural education initiatives impacting thousands of students and teachers
Quality as a Competitive Advantage
With global production capacity set to expand to 230,000 liters across Suzhou and Hangzhou, Innovent maintains 100% GMP certification while pioneering dual-sourcing strategies for critical raw materials. A 100% batch success rate and perfect audit performance validate its uncompromising standards.
- 122 supplier quality audits conducted, with intensive training delivered to 95% of supply chain partners
- New Hangzhou ADC manufacturing hub advances oncology pipeline scalability
- ISO 14001 and ISO 45001 certifications maintained across facilities
- Water recycling initiatives saved 51,100 tons annually
Cultivating a Culture of Innovation
Employee retention hitting 96.8% underscores Innovent’s investment in talent: 51% female workforce representation and 44.2% women in management signal a commitment to inclusive leadership. The “Innovent Beginning” program injected 2,100 new graduates into R&D and commercial pipelines across 20 provinces.
Green Chemistry in Action
Innovent’s sustainability strategy extends beyond compliance. Energy use dropped 29% year-over-year, and its Shanghai R&D center earned LEED Gold certification for energy-efficient design. By quantifying emissions footprints and setting science-based reduction targets, the company aims to decouple growth from environmental strain—a pressing challenge in a capital-intensive industry.
“Our Shanghai lab isn’t just a marvel of glass towers,” a spokesperson noted. “It’s a blueprint for how biopharma can conduct 21st-century R&D without compromising ecological integrity.”
Looking Ahead
As Innovent positions itself in the league of global biotech titans, balancing profitability with ESG performance remains central. With 30+ partnerships across continents and a 15-drug portfolio already transforming patient journeys, the company’s aspiration—”to be both disruptor and steward”—reflects a paradigm shift redefining industry priorities.
“Biology doesn’t stop at borders,” Yu concluded. “Neither should our ambition—or our accountability.”
About Innovent: Founded in 2011, Innovent bridges innovation with accessibility through blockbuster therapies for cancer and chronic diseases. Beyond drug approvals, its collaborations with players like Eli Lilly and Sanofi reimagine how partnerships accelerate global health equity. For deeper insights, visit www.innoventbio.com.
|
Heads-Up: |
|
Ramucirumab (Cyramza), Selpercatinib (Retsevmo), and Pirtobrutinib (Jaypirca) remain the intellectual property of Eli Lilly and Company. |
Forward-Looking Disclosure: This report contains projections subject to market risks, regulatory changes, and geopolitical volatility. Innovent declines to provide ongoing updates to these statements.
View original content: Source
SOURCE: Innovent Biologics
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/398.html
